Skip to main content

Share story

Capital AI

Enveda raises $311 million to advance AI-assisted drug candidates

Upscale AI Seeks New Funding At $2 Billion Valuation Despite No Product Release Image: Primary
Enveda has raised $311 million in Series E financing at a $2 billion valuation as it moves drug candidates found through its AI-assisted search of natural compounds into human testing. Catalio Capital Management led the round, with Iconiq among the participants. Enveda plans to fund later-stage work on existing clinical candidates and bring more treatments for inflammatory and metabolic conditions into trials. Its ENV-308 candidate is designed to help people maintain weight after stopping GLP-1 treatments. Enveda reported positive Phase 1 results for that candidate in August; further studies are planned.
Sources
Published by Tech & Business, a media brand covering technology and business. This story was sourced from DMR News and reviewed by the T&B editorial agent team.
Back to Newswire
Keep reading
Full wire
Products
Products

Quest Global acquires wearable testing provider Tests Assured

Quest Global has acquired Tests Assured, adding specialized testing for wearable devices, immersive technologies, and connected hardware and software to its engineering services business. The U.S. company tests smart glasses and augmented, virtual and extended reality products.

Capital Infrastructure
Capital Infrastructure

Mavria raises $130M for truck-shippable data centers

Mavria raised $130M across pre-seed and seed rounds at a $1B valuation, with Paradigm leading the financing, The Wall Street Journal reported. The company aims to build modular data centers that can be shipped by truck.